Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Sonus Pharmaceuticals' EchoGen

Executive Summary

Sonus Pharmaceuticals' EchoGen: NDA submitted Aug. 12 for perflenapent emulsion, a fluorocarbon-based ultrasound contrast agent. Filing triggers $4 mil. milestone payment from U.S. marketer Abbott Labs. Sonus also recently earned a $3 mil. milestone payment from Daiichi, which will market and distribute product in Pacific Rim. According to Bothell, Wash.-based Sonus, EchoGen has a diagnostic sensitivity of 89%, specificity of 97%, a positive predictive value of 98%, negative predictive value of 84% and an overall accuracy of 92%...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel